DIA Webinar on Critical Chain in the Pharmaceutical Industry
Date: September 23, 2010
Time: 11:00 AM -12:30 PM ET
MODERATOR:
John Sun, PhD, MBA, PMP
Global Program Team Director, Novartis Pharmaceuticals Corporation
Global Development Franchise, Established Medicines
PRESENTER:
Andreas Scherer, PhD
General Manager, ProChain Solutions Inc.
Explore the Key Principles of the Critical Chain Methodology as Well as the Basics of Buffer Management.
This highly interactive webinar will provide attendees with an opportunity to fully explore how Critical Chain improves the execution of projects in the pharmaceutical industry, particularly in the areas of project management, R&D functions, and executive sponsorship.
FEATURED TOPICS
- Critical Chain at the team level
- Executive sponsorship
- Sustainability
- Scalability
- Change management
WHO SHOULD ATTEND
Pharmaceutical executives, functional managers, and project managers involved in:
- Information technology
- Product development
- Clinical research
LEARNING OBJECTIVES
At the conclusion of this webinar, participants should be able to:
- Explain the key elements of the critical chain methodology
- Describe the impact of critical chain at the team, functional and executive levels
Registration details can be found here!
Lilly’s CEO Lechleiter on Critical Chain
In a recent Business Week article Lilly’s CEO Lechleiter outlined his strategy to deal with business challenges his company is facing: “Lilly stands to lose $10 billion in annual revenues between now and the end of 2016—almost half its 2009 sales—as patents on three key drugs expire. To replace that, the company must pick up the pace of drug development.” Lilly is not alone. Almost any major pharmaceutical company faces similiar issues. In order to speed up their drug development process, Lilly uses Critical Chain as their sole operating platform to manage drug development projects. Here you find the entire article.
Impact of Critical Chain in Drug Development at Eli Lilly
It is rare to get portfolio level data on the impact of Critical Chain. Steven Paul, PhD, President of Lilly Reseach Laboratories, outlines in an Interview with PharmExec the three pillars of Lilly’s business strategy. The first one is the global of adoption of Critical Chain on all Lilly’s R&D projects. He says, ”One hundred percent of the projects using critical chain methodology are on track, either at or ahead of their milestones, as compared to about 60 percent of our traditional development projects.” He also mentioned that Lilly is planning to have all projects under Critical Chain by the end of 2009. Lilly had presented early results of their Critical Chain rollout in two presentations at ProChain’s 9th annual user conference back in 2008.
Here you find the entire interview.
If you like to read up on this, then you might find these links helpful. Enjoy!
Indiana Economic Digest on Lilly’s new stragey
BioPharma Today on Lilly’s new strategy
The Point on Critical Chain in the Life Science Industry
The Point on the recent wave of mergers in pharma
The Point on rapid & reliable project delivery
